AbbVie (ABBV) EPS (Basic) Growth (3y) (2015 - 2026)
AbbVie (ABBV) EPS (Basic) Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.75 Bn | 633.00 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 470.62 Bn | 464.05 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 376.18 Bn | 369.04 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 303.75 Bn | 296.06 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 257.67 Bn | 252.77 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 182.04 Bn | 178.86 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 106.27 Bn | 102.10 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.23% |
| Mar 31, 2026 | 109.43% |
| Dec 31, 2025 | -9.75% |
| Sep 30, 2025 | -63.75% |
| Jun 30, 2025 | 0.50% |
| Mar 31, 2025 | -34.01% |
| Dec 31, 2024 | -26.11% |
| Sep 30, 2024 | -21.05% |
| Jun 30, 2024 | 21.34% |
| Mar 31, 2024 | -27.19% |
| Dec 31, 2023 | 173.44% |
| Sep 30, 2023 | -8.31% |
| Jun 30, 2023 | 65.79% |
| Mar 31, 2023 | -26.56% |
| Dec 31, 2022 | -9.63% |
| Sep 30, 2022 | 20.60% |
| Jun 30, 2022 | 1.55% |
| Mar 31, 2022 | 15.20% |
| Dec 31, 2021 | 57.79% |
| Sep 30, 2021 | -0.39% |